Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease

被引:468
作者
Egami, Kimiyasu
Muta, Hiromi
Ishii, Masahiro
Suda, Kenji
Sugahara, Yoko
Iemura, Motofumi
Matsuishi, Toyojiro
机构
[1] Kurume Univ, Dept Pediat, Kurume, Fukuoka 830, Japan
[2] Kitasato Univ, Dept Pediat, Sagamihara, Kanagawa 228, Japan
关键词
D O I
10.1016/j.jpeds.2006.03.050
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objectives The objective of this study was to find the predictors and generate a prediction score of resistance to intravenous immunoglobulin (IVIG) in patients with Kawasaki disease (KD). Study design Patients diagnosed as having KD were sampled when they received initial high-dose IVIG treatment (2 g/kg dose) within 9 days of illness (n = 320). These patients were divided into 2 groups: the resistance (n = 41) and the responder (n = 279). The following data were obtained and compared between resistance and responder: age, sex, illness days at initial treatment, and laboratory data. Results Multivariate logistic regression analysis identified age, illness days, platelet count, alanine aminotransferase (ALT), and C-reactive protein (CRP) as significant predictors for resistance to IVIG. We generated prediction score assigning I point for (1) infants less than 6 months old, (2) before 4 days of illness, (3) platelet count <= 30 x 10(10)/L, (4) CRP >= 8 mg/dL, as well as 2 points for (5) ALT >= 80 IU/L. Using a cut-off point of 3 and more with this prediction score, we could identify the IVIG-resistant group with 78% sensitivity and 76% specificity. Conclusions Resistance to IVIG treatment can be predicted using age, illness days, platelet. count, ALT, and CRP. Randomized, multicenter clinical trials are necessary to create a new strategy to treat these high-risk patients.
引用
收藏
页码:237 / 240
页数:4
相关论文
共 28 条
[1]   Infliximab treatment for refractory Kawasaki syndrome [J].
Burns, JC ;
Mason, WH ;
Hauger, SB ;
Janai, H ;
Bastian, JF ;
Wohrley, JD ;
Balfour, I ;
Shen, CA ;
Michel, ED ;
Shulman, ST ;
Melish, ME .
JOURNAL OF PEDIATRICS, 2005, 146 (05) :662-667
[2]   Intravenous gamma-globulin treatment and retreatment in Kawasaki disease [J].
Burns, JC ;
Capparelli, EV ;
Brown, JA ;
Newburger, JW ;
Glode, MP .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1998, 17 (12) :1144-1148
[3]   A comparison of C/B ratios from studies using receiver operating characteristic curve analysis [J].
Cantor, SB ;
Sun, CC ;
Tortolero-Luna, G ;
Richards-Kortum, R ;
Follen, M .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (09) :885-892
[4]   Coronary artery dimensions may be misclassified as normal in Kawasaki disease [J].
de Zorzi, A ;
Colan, SD ;
Gauvreau, K ;
Baker, AL ;
Sundel, RP ;
Newburger, JW .
JOURNAL OF PEDIATRICS, 1998, 133 (02) :254-258
[5]   Immunoglobulin failure and retreatment in Kawasaki disease [J].
Durongpisitkul, K ;
Soongswang, J ;
Laohaprasitiporn, D ;
Nana, A ;
Prachuabmoh, C ;
Kangkagate, C .
PEDIATRIC CARDIOLOGY, 2003, 24 (02) :145-148
[6]   Prediction of non-responsiveness to intravenous high-dose γ-globulin therapy in patients with Kawasaki disease at onset [J].
Fukunishi, M ;
Kikkawa, M ;
Hamana, K ;
Onodera, T ;
Matsuzaki, K ;
Matsumoto, Y ;
Hara, J .
JOURNAL OF PEDIATRICS, 2000, 137 (02) :172-176
[7]  
FURUKAWA S, 1993, RIUMACHI KA, V9, P165
[8]   Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease [J].
Han, RK ;
Silverman, ED ;
Newman, A ;
McCrindle, BW .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2000, 154 (07) :694-699
[9]  
Harada Kensuke, 1991, Acta Paediatrica Japonica, V33, P805
[10]   Treatment of acute Kawasaki disease: Aspirin's role in the febrile stage revisited [J].
Hsieh, KS ;
Weng, KP ;
Lin, CC ;
Huang, TC ;
Lee, CL ;
Huang, SM .
PEDIATRICS, 2004, 114 (06) :E689-E693